{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:13:57Z","timestamp":1786407237182,"version":"build-2736575974"},"reference-count":29,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Novartis Pharma AG"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","aaojournal.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.ophtha.2014.12.033","type":"journal-article","created":{"date-parts":[[2015,1,28]],"date-time":"2015-01-28T23:49:45Z","timestamp":1422488985000},"page":"939-948","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":153,"title":["Efficacy and Safety of Intravenous Secukinumab in Noninfectious Uveitis Requiring Steroid-Sparing Immunosuppressive Therapy"],"prefix":"10.1016","volume":"122","clinical-trial-number":[{"clinical-trial-number":"nct00685399","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Erik","family":"Letko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Stephen","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Pleyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell","family":"Brigell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia L.","family":"Grosskreutz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2014.12.033_bib1","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/BF00163549","article-title":"The natural history of uveitis","volume":"14","author":"Nussenblatt","year":"1990","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.12.033_bib2","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1136\/bjo.2003.037226","article-title":"Degree, duration, and causes of visual loss in uveitis","volume":"88","author":"Durrani","year":"2004","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.12.033_bib3","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.preteyeres.2011.06.005","article-title":"Understanding uveitis: the impact of research on visual outcomes","volume":"30","author":"de Smet","year":"2011","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.ophtha.2014.12.033_bib4","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.ophtha.2003.06.014","article-title":"Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study","volume":"111","author":"Gritz","year":"2004","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2014.12.033_bib5","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1001\/jamaophthalmol.2013.4237","article-title":"Incidence and prevalence of uveitis: results from the Pacific Ocular Inflammation Study","volume":"131","author":"Acharya","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.12.033_bib6","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.ajo.2008.09.014","article-title":"Incidence and prevalence of uveitis in Veterans Affairs Medical Centers of the Pacific Northwest","volume":"146","author":"Suhler","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.12.033_bib7","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/eye.2011.255","article-title":"Current concepts and future directions in the pathogenesis and treatment of non-infectious intraocular inflammation","volume":"26","author":"Lee","year":"2012","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ophtha.2014.12.033_bib8","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1159\/000336185","article-title":"Corticosteroid-sparing agents: conventional systemic immunosuppressants","volume":"51","author":"Kruh","year":"2012","journal-title":"Dev Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.12.033_bib9","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1159\/000336186","article-title":"Corticosteroid-sparing agents: new treatment options","volume":"51","author":"Tomkins-Netzer","year":"2012","journal-title":"Dev Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.12.033_bib10","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.preteyeres.2011.11.004","article-title":"Interplay between innate and adaptive immunity in the development of non-infectious uveitis","volume":"31","author":"Willermain","year":"2012","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.ophtha.2014.12.033_bib11","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/nrd3794","article-title":"Targeting Il-17 and Th17 cells in chronic inflammation","volume":"11","author":"Miossec","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ophtha.2014.12.033_bib12","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nm1585","article-title":"TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27\/STAT1","volume":"13","author":"Amadi-Obi","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.ophtha.2014.12.033_bib13","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1080\/030097402320318387","article-title":"Cytokine profile in Beh\u00e7et\u2019s disease patients: relationship with disease activity","volume":"31","author":"Hamzaoui","year":"2002","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.ophtha.2014.12.033_bib14","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1167\/iovs.07-1390","article-title":"Upregulated IL-23 and IL-17 in Beh\u00e7et patients with active uveitis","volume":"49","author":"Chi","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2014.12.033_bib15","doi-asserted-by":"crossref","first-page":"R99","DOI":"10.1186\/ar3824","article-title":"Inhibition of Th17 differentiation by anti-TNF-alpha therapy in uveitis patients with Beh\u00e7et\u2019s disease","volume":"14","author":"Sugita","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.ophtha.2014.12.033_bib16","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.1167\/iovs.07-0251","article-title":"Characterization of IL-17+ interphotoreceptor retinoid-binding protein-specific T cells in experimental autoimmune uveitis","volume":"48","author":"Peng","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2014.12.033_bib17","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1080\/02713680902741696","article-title":"Suppression of experimental autoimmune uveoretinitis by anti-IL-17 antibody","volume":"34","author":"Zhang","year":"2009","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.ophtha.2014.12.033_bib18","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.cyto.2008.12.019","article-title":"Interleukin-17 causes neutrophil mediated inflammation in ovalbumin-induced uveitis in DO11.10 mice","volume":"46","author":"Zhang","year":"2009","journal-title":"Cytokine"},{"key":"10.1016\/j.ophtha.2014.12.033_bib19","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3001107","article-title":"Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis","volume":"2","author":"Hueber","year":"2010","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ophtha.2014.12.033_bib20","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ophtha.2012.09.040","article-title":"Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials","volume":"120","author":"Dick","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2014.12.033_bib21","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/j.ophtha.2005.02.020","article-title":"Mycophenolate mofetil therapy for inflammatory eye disease","volume":"112","author":"Thorne","year":"2005","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2014.12.033_bib22","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.ophtha.2009.04.020","article-title":"Methotrexate for ocular inflammatory disease","volume":"116","author":"Gangaputra","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2014.12.033_bib23","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nrd2805","article-title":"Averting inflammation by targeting the cytokine environment","volume":"9","author":"Kopf","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ophtha.2014.12.033_bib24","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3109\/09273948.2012.723107","article-title":"Systematic review of anti-tumor necrosis factor-alpha therapy for treatment of immune-mediated uveitis","volume":"21","author":"Cordero-Coma","year":"2013","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.ophtha.2014.12.033_bib25","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3109\/09273948.2011.633205","article-title":"Infliximab and adalimumab for uveitis","volume":"20","author":"Martel","year":"2012","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.ophtha.2014.12.033_bib26","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jaut.2008.05.001","article-title":"High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis","volume":"31","author":"Yeh","year":"2008","journal-title":"J\u00a0Autoimmun"},{"key":"10.1016\/j.ophtha.2014.12.033_bib27","doi-asserted-by":"crossref","first-page":"7462","DOI":"10.1073\/pnas.96.13.7462","article-title":"Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I\/II clinical trial","volume":"96","author":"Nussenblatt","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ophtha.2014.12.033_bib28","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.ophtha.2004.12.034","article-title":"Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series","volume":"112","author":"Nussenblatt","year":"2005","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2014.12.033_bib29","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1136\/gutjnl-2011-300755","article-title":"Switch to adalimumab in patients with Crohn\u2019s disease controlled by maintenance infliximab: prospective randomised SWITCH trial","volume":"61","author":"Van Assche","year":"2012","journal-title":"Gut"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016164201401224X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016164201401224X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,25]],"date-time":"2018-09-25T19:29:42Z","timestamp":1537903782000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016164201401224X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S016164201401224X"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2014.12.033","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725335363.793529303","asserted-by":"object"}]},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Intravenous Secukinumab in Noninfectious Uveitis Requiring Steroid-Sparing Immunosuppressive Therapy","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2014.12.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}